RxDoctor Payments Data

Megan Mackenzie, DO

Neurology · Centerville, OHNPI 1912274994

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $41,384 of the $63,881 with a category attached, or 64.8%. 60 manufacturers reported payments, led by Lilly USA, LLC at 51.1% of the total. Reporting peaked in 2021 at $20,713 and has fallen 79.1% since, to $4,322 in 2025.

$63,881in general payments, 2019–2025

Across 1,203 payments — averaging $53.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$33K
  • Biohaven Pharmaceuticals, Inc.$9K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • AbbVie$3K
  • Novartis$2K
  • Amgen$1K
  • plus $11K from 54 others
$53,301in research payments, 2019–2025

Across 85 payments — averaging $627.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Products Limited$33K
  • UCB SA$10K
  • Pfizer$10K

What the payments were for

  • Consulting fees$2,8004%
  • Speaking & faculty fees$41,38465%
  • Grants$440%
  • Travel & lodging$240%
  • Food & beverage$19,16030%
  • Education$4681%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC126$32,674
Biohaven Pharmaceuticals, Inc.24$8,942
Biohaven Pharmaceutical Holding Company Ltd.19$4,908
AbbVie(2 entities)230$3,322
Novartis129$1,660
Amgen(2 entities)72$1,301
Teva Pharmaceuticals USA, Inc.58$934
MDD US Operations, LLC30$907
EMD Serono, Inc.34$807
Biogen52$801
UCB, Inc.42$679
Pfizer43$654
Supernus Pharmaceuticals, Inc.31$504
AstraZeneca(2 entities)27$479
SK Life Science, Inc.25$468
Sanofi24$450
Acadia Pharmaceuticals Inc26$442
Neurocrine Biosciences, Inc.16$318
Lundbeck LLC16$303
Amneal Pharmaceuticals LLC17$302
Genentech USA, Inc.20$294
Acorda Therapeutics, Inc13$218
Sunovion Pharmaceuticals Inc.13$167
Johnson & Johnson7$152
Eisai Inc.7$146
Argenx US, Inc.6$140
Greenwich Biosciences, Inc.7$137
Jazz Pharmaceuticals Inc.6$132
Adamas Pharmaceuticals, Inc.9$130
CSL Behring6$130
Abbott1$129
Avanir Pharmaceuticals, Inc.6$89
Zyla Life Sciences, Inc.6$87
Merz Pharmaceuticals, LLC4$78
Medtronic1$78
Ipsen Biopharmaceuticals, Inc4$65
Neurelis, Inc.4$64
Takeda Pharmaceuticals U.S.A., Inc.3$57
Sumitomo Pharma America, Inc.3$57
Amylyx Pharmaceuticals, Inc.3$53
Merz North America, Inc.3$48
E.r. Squibb & Sons, L.L.C.3$47
TG Therapeutics, Inc.2$42
Vanda Pharmaceuticals Inc.1$39
GE HealthCare2$39
Harmony Biosciences LLC2$32
Alnylam Pharmaceuticals Inc.1$28
Kyowa Kirin, Inc.2$27
Grifols USA, LLC2$27
Otsuka America Pharmaceutical, Inc.1$26
Catalyst Pharmaceuticals, Inc.1$25
Averitas Pharma Inc.1$25
Insightec,inc1$24
Vertical Pharmaceuticals, LLC2$24
Promius Pharma LLC1$22
Scilex Pharmaceuticals Inc.1$21
Philips North America LLC1$20
Banner Life Sciences, LLC1$20
Octapharma USA, Inc.1$19
Bristol Myers Squibb1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,881 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio →

Medicare billing

Part B allowed, 2024
$229,460
Medicare patients
332
Services billed
23,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina33$46,797
QuliptaAtogepant21$22,335
UbrelvyUbrogepant17$18,634
Sumatriptan Succinate17$7,965
Pyridostigmine Bromide12$5,020
Zonisamide19$1,187
Memantine Hcl32$628
Gabapentin34$419
Primidone28$305
Tizanidine Hcl57$279
Divalproex Sodium14$229
Carbidopa-LevodopaCarbidopa/Levodopa14$229
Donepezil Hcl19$139
Amitriptyline Hcl13$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy$3,322$87,76571 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$302$5,02012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Centerville

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →